Company news
Research Alliance Corporation III news
Latest news releases, newest first.
Oak Hill Bio and Research Alliance Corporation III Announce Business Combination Agreement to Create Publicly Listed Rare Disease Biotechnology Company to Advance Antisense Oligonucleotide Therapy Rugonersen for Angelman Syndrome
July 27, 2026
Research Alliance Corp III: Net income $(65,249), EPS $(0.06) — 10-Q Summary
July 2, 2026
Research Alliance Holdings III LLC Discloses Investment at Research Alliance Corporation III with 14.7% Stake
May 29, 2026
Research Alliance Corp III prices IPO for $75M, deposits $75M in trust
May 28, 2026
Research Alliance III Closes $75 Million IPO; Sets Trust And $2.75 Million Sponsor Private Placement
May 21, 2026
Research Alliance Corporation III announces pricing of $75 million initial public offering
May 20, 2026
Decks
- Research Alliance Corp III — SPAC Merger (September 2026)
SPAC merger · 27 slides · Sep 16, 2026
- Research Alliance Corp III — SPAC Merger (July 2026)
SPAC merger · 27 slides · Jul 27, 2026